Are pazopanib and pazopanib the same drug?

Pazopanib/ Pazopanib and pazopanib actually refer to the same drug, but with slightly different expressions, which is not uncommon in medical literature or drug descriptions. Pazopanib is a targeted therapy drug that belongs to the class of Multi-targeted Tyrosine Kinase Inhibitors (mTKIs). It is mainly used to treat advanced renal cell carcinoma and soft tissue sarcoma. The drug achieves therapeutic effects by blocking blood supply by inhibiting tumor angiogenesis and tumor cell growth.

Pazopanib can block the activity of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR). These receptors play a key role in tumor growth and blood vessel formation. In clinical applications, pazopanib is often used as a first-line treatment option, especially for patients with advanced or metastatic renal cell carcinoma.

Pazopanib must be used under the guidance of a doctor because it has certain side effects and contraindications. For example, it may cause high blood pressure, hand-foot skin reactions, fatigue, nausea, diarrhea and other adverse reactions. In addition, pregnant women should avoid its use due to possible adverse effects on the fetus. During the medication process, the doctor will adjust the dosage according to the patient's specific condition to achieve the best therapeutic effect and reduce side effects.

In short, pazopanib, as an important anti-tumor drug, plays an important role in the treatment of advanced renal cell carcinoma and soft tissue sarcoma, but its use must be strictly followed by medical instructions to ensure safety and effectiveness. The name pazopanib is practically equivalent to pazopanib and refers to the same drug.